Infectious Disease Molecular Diagnostics Market Unlocks Growth Through Innovative Molecular Technologies

The global infectious disease molecular diagnostics market is expected to witness steady growth as healthcare systems increasingly adopt advanced diagnostic technologies for accurate and early disease detection. According to Straits Research, the global infectious disease molecular diagnostics market size was valued at USD 42.88 billion in 2025 and is projected to grow from USD 45.66 billion in 2026 to USD 75.57 billion by 2034, registering a CAGR of 6.5% during the forecast period 2026–2034.

Molecular diagnostics plays a critical role in identifying infectious agents by detecting genetic material or disease-specific biological markers. These tests are widely used to diagnose bacterial, viral, fungal, and parasitic infections with greater precision than many conventional testing methods. Techniques such as polymerase chain reaction (PCR), ELISA, sequencing, in situ hybridization, and nucleic acid amplification have transformed clinical and public health laboratories by enabling faster and more accurate disease identification.

Technological Advancements Drive Market Growth

The introduction of technologically advanced diagnostic products is one of the primary factors driving market expansion. Companies are focusing on improving diagnostic accuracy, portability, speed, and cost-efficiency through continuous product development and research.

Advanced platforms such as Roche Diagnostics’ Cobas HPV test and Cepheid’s GeneXpert-based tuberculosis assays demonstrate how innovation is improving infectious disease testing. The rising adoption of technologies such as ELISA, fluorescence in situ hybridization, PCR, and high-throughput molecular testing is expected to further support market growth.

As infectious diseases evolve and resistance patterns become more complex, diagnostic test menus must continue expanding to address emerging pathogens and changing clinical requirements.

Rising Prevalence of Infectious Diseases Supports Demand

The growing burden of infectious diseases is another major factor accelerating demand for molecular diagnostics. Hospital-acquired infections, sexually transmitted infections, respiratory diseases, tuberculosis, HPV, sepsis, and drug-resistant infections continue to create strong demand for rapid and reliable testing.

Molecular diagnostics allows clinicians to detect infections at an early stage, support targeted treatment decisions, and reduce the risk of disease transmission. The rising prevalence of sexually transmitted infections, including HIV, HPV, chlamydia, gonorrhea, and syphilis, is also expected to significantly boost market growth.

Regulatory Complexity Remains a Market Challenge

Despite strong growth potential, the infectious disease molecular diagnostics market faces challenges due to complex regulatory approval processes.

Molecular diagnostic tests are increasingly used to support critical medical decisions, which requires strict validation, quality control, and post-market monitoring. Regulatory agencies continue to evaluate product performance, safety, and claims to ensure reliability. These requirements can increase development timelines and costs for manufacturers, potentially limiting market expansion.

Emerging Economies Create Growth Opportunities

Developing economies such as India, South Korea, Brazil, and Mexico are expected to offer strong opportunities for market participants. These countries are experiencing rising disease prevalence, expanding healthcare infrastructure, increasing disposable income, growing medical tourism, and larger patient populations.

Asia-Pacific is becoming an attractive region for diagnostic companies due to improving healthcare access, growing laboratory capacity, and rising demand for advanced testing solutions. Less complex data requirements in certain emerging markets may also support faster product adoption compared to highly regulated regions.

Segmentation Analysis

Based on product, the market is segmented into instruments, reagents, and services. The reagents segment dominates the global market and is expected to grow at a CAGR of 3.1% during the forecast period. Reagents are widely used in clinical and research settings, supporting accurate, standardized, and efficient diagnostic results. The development and distribution of new reagents are expected to remain important contributors to market growth.

By application, the market includes respiratory diseases, tuberculosis, meningitis, gastrointestinal tract infections, HPV, sexually transmitted infections, sepsis, drug resistance disease, and other infectious diseases. The sexually transmitted infections segment holds the largest market share and is projected to grow at a CAGR of 9.39%, supported by high STI prevalence and increasing demand for advanced multiplex assays.

Based on technology, the market includes polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, chips and microarrays, mass spectrometry, sequencing, transcription-mediated amplification, and others. The PCR segment is the largest contributor and is expected to grow at a CAGR of 2.1%. PCR remains a gold-standard molecular diagnostic technology due to its reliability, sensitivity, and broad use in detecting infectious diseases.

By end-user, the market is segmented into hospitals, clinics, diagnostics laboratories, and research institutes. The diagnostics laboratories segment dominates the market due to high testing volumes, strong procedure capacity, and growing collaboration between laboratories and healthcare institutions.

Regional Analysis

North America dominates the global infectious disease molecular diagnostics market and is expected to maintain a significant position during the forecast period. The region’s leadership is supported by advanced healthcare infrastructure, strong adoption of molecular testing, high disease surveillance capacity, and the presence of leading diagnostics companies.

The United States remains a key contributor due to growing demand for rapid infectious disease testing, strong laboratory networks, and continued investment in advanced diagnostic technologies.

Europe is expected to be the fastest-growing regional market during the forecast period. Growth is supported by rising adoption of molecular diagnostics, increasing healthcare modernization, and growing demand for accurate infectious disease testing across major European countries.

Asia-Pacific is also emerging as a high-potential region due to increasing healthcare spending, rising disease awareness, expanding diagnostic laboratory networks, and growing adoption of digital healthcare and molecular testing technologies.

Key Market Players

Major companies operating in the global infectious disease molecular diagnostics market include Abbott, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Danaher Corporation, Hologic, Inc., Illumina, Inc., Grifols S.A., Qiagen, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, and Sysmex Corporation.

These companies are focusing on product innovation, assay development, technology partnerships, and diagnostic platform expansion to strengthen their presence in the global market.

Recent Developments

In February 2023, C-CAMP InDx announced the InDx 2.0 National Diagnostics Catapult to scale up India’s molecular diagnostics capacity for COVID-19 and beyond.

In January 2023, Alveo Technologies and the Government of Barbados collaborated to co-develop advanced molecular disease diagnostics across multiple end markets.

Future Outlook

The infectious disease molecular diagnostics market is expected to grow steadily as healthcare systems prioritize early detection, accurate diagnosis, and targeted treatment. Rising infectious disease prevalence, increasing demand for rapid testing, expanding molecular diagnostic platforms, and growing opportunities in emerging economies will continue to support market expansion.

Although regulatory complexity and approval challenges remain, continued innovation in PCR, sequencing, multiplex testing, and point-of-care diagnostics is expected to strengthen the future outlook of the market.

Explore detailed Infectious Disease Molecular Diagnostics Market insights and strategic growth opportunities with Straits Research.

https://straitsresearch.com/report/infectious-disease-molecular-diagnostics-market

About Straits Research

Straits Research is a global market research and consulting firm providing actionable business intelligence, customized research solutions, and industry analysis across multiple sectors. The company delivers comprehensive market reports, competitive insights, and forecasting that help organizations make informed strategic decisions and identify emerging growth opportunities worldwide.